🟠 Moderate Evidence
A two-cohort observational study published in PLOS Medicine has found that socioeconomic status (SES) meaningfully influences how children respond to obesity treatment in some European healthcare systems, though the relationship differs substantially between countries. Among 31,293 children with obesity who received structured health behavior and lifestyle interventions in Sweden and Germany over three years, treatment effectiveness was stratified by SES in Germany but not Sweden, revealing important healthcare equity gaps.
Key takeaways
- Children from lower socioeconomic backgrounds in Germany showed significantly smaller reductions in body mass index after two years of obesity treatment compared to higher SES peers
- This SES-related treatment gap was not observed in Sweden, suggesting healthcare system design plays a critical role
- Lower baseline SES was associated with higher starting obesity severity in both countries
Study at a Glance
| Source | PLOS Medicine |
| Study type | Two-cohort observational study |
| Sample size | 31,293 children with obesity (18,588 Swedish, 12,705 German) |
| Population | Children receiving health behavior and lifestyle obesity treatment |
| Countries | Sweden and Germany |
| Follow-up duration | 3 years |
BMI Improvement Gap Widens by Socioeconomic Status in Germany
Change in BMI standard deviation score (SDS) after 2 years of obesity treatment, by socioeconomic quintile
Source: Auzanneau et al., PLOS Medicine, 2024 | Data: German/Austrian/Swiss Adiposity Patients Register (APV)
SES Predicts Obesity Severity and Treatment Access
The research team, led by Dr. Marie Auzanneau and colleagues, analyzed data from two national obesity treatment registries: the Swedish Childhood Obesity Treatment Register (BORIS) and the German/Austrian/Swiss Adiposity Patients Register (APV). The study found that in both countries, children from lower SES backgrounds presented with significantly higher baseline body mass index (BMI) at treatment entry—a pattern suggesting that socioeconomic barriers may delay diagnosis and referral for specialist care.
In Sweden, where treatment was delivered through a publicly funded system with universal access, SES showed no statistically significant association with change in BMI over the three-year treatment period (p = 0.143). This null finding is notable: it indicates that when healthcare systems remove financial and access barriers, SES no longer predicts treatment response. See our Clinical Updates section for related treatment guidelines.
Germany Shows Persistent SES-Related Treatment Inequality
In contrast, the German cohort revealed a clear SES gradient in treatment outcomes. Children in the highest SES quintile achieved a mean BMI SDS reduction of −0.36 (95% confidence interval [−0.38, −0.34]) after two years of treatment, compared to −0.24 in the lowest SES quintile, yielding a clinically meaningful gap of −0.12 SDS. This difference persisted at the three-year mark, suggesting that the inequality was not merely transient.
The researchers adjusted their analyses for sex, baseline obesity class, age group, and migration background, but the SES effect remained robust in Germany. This implies that unmeasured or structural factors—such as differential access to nutritional counseling, physical activity facilities, or transportation to appointments—may mediate the observed inequality. The Health Policy section explores healthcare equity frameworks relevant to these findings.
Children from the highest socioeconomic quintile in Germany achieved 50% greater BMI reduction than those from the lowest quintile after two years of structured obesity treatment—a gap that narrowed only marginally by year three.
— Dr. Marie Auzanneau and colleagues, Karolinska Institute & Charité University Hospital (PLOS Medicine, 2024)
Early Treatment Discontinuation: Another SES Marker
The study also examined treatment discontinuation within six months as a secondary outcome. Early dropout from obesity treatment programs is a well-documented barrier to success, and SES may influence willingness or ability to engage long-term. The analysis revealed that both countries experienced differential dropout patterns by SES, though the magnitude was not detailed in the abstract. Early intervention to identify and support at-risk populations—particularly in lower-SES settings—may improve adherence and sustained weight loss outcomes.
What this means
Frequently asked questions
Why did Sweden show no SES effect when Germany did?
Sweden’s publicly funded healthcare model offers universal access to obesity treatment at no point-of-care cost, potentially removing financial barriers that lower-SES families face in Germany. Healthcare system design—not population differences—likely explains the divergence. This underscores the role of policy in health equity outcomes.
Does this study prove that low SES causes poor obesity treatment outcomes?
No. The study is observational and cannot establish causation. It documents an association between SES and treatment response in Germany but not Sweden. The true mechanisms may include differential access to allied services (dietitians, exercise specialists), transportation barriers, time availability, or psychosocial stress—all of which correlate with SES but were not directly measured.
Are these findings relevant outside Europe?
Likely yes, but with caveats. The pattern observed in Germany (SES-stratified outcomes) may reflect healthcare systems in other middle-income or mixed-payer countries. The Swedish pattern (equitable outcomes) may reflect systems with universal coverage. Researchers should test these findings in diverse healthcare contexts to inform global obesity treatment equity strategies.
This study adds to growing evidence that healthcare equity in pediatric obesity treatment depends not only on individual and family factors but on the structural design of healthcare systems themselves. Future research should identify specific mechanisms—transportation, cost, cultural competence, appointment availability—through which SES influences treatment engagement and efficacy, enabling targeted policy and clinical interventions. For more on obesity treatment and lifestyle medicine, visit the Clinical Updates section.
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Editorial standards. This article was produced under the GMJ News editorial process, with oversight by the GMJ Editorial Board. Our editorial process. Spotted an error? Contact the editorial team.
